Hoppe v. Smithkline Beecham Corp.

437 F. Supp. 2d 331, 2006 U.S. Dist. LEXIS 46746, 2006 WL 1805968
CourtDistrict Court, E.D. Pennsylvania
DecidedJune 29, 2006
DocketCIVA 05CV05112
StatusPublished
Cited by6 cases

This text of 437 F. Supp. 2d 331 (Hoppe v. Smithkline Beecham Corp.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hoppe v. Smithkline Beecham Corp., 437 F. Supp. 2d 331, 2006 U.S. Dist. LEXIS 46746, 2006 WL 1805968 (E.D. Pa. 2006).

Opinion

EXPLANATION AND ORDER

ANITA B. BRODY, District Judge.

Plaintiff Jon R. Hoppe is the surviving spouse of Margaret O. Hoppe (“Mrs. Hoppe”). Mrs. Hoppe committed suicide on September 27, 2002, after having taken the anti-depressant Paxil for approximately three months. In this diversity action, plaintiff brings wrongful death and survival actions under Wisconsin law against those who designed, manufactured, and currently distribute Paxil, alleging that Mrs. Hoppe’s death was caused by defendants’ failure to disclose Paxil’s risk of causing suicidality to the public and the healthcare community.

*334 Plaintiff filed the complaint on September 26, 2005. On December 2, 2005, after answering, defendants filed a motion for summary judgment. On January 6, 2006, I ordered that discovery in the case would be stayed pending the resolution of defendants’ motion. Before me is defendants’ motion for summary judgment. For the reasons stated below, I will grant in part and deny in part the motion.

I. Factual Allegations 1

Paxil is the trade name for the prescription medicine Paroxetine, an anti-depressant that was designed, tested, labeled, distributed, marketed, and (for the purposes of this litigation) manufactured by defendants. (See Answer ¶ 8.)

Internal documents show that defendants knew as early as 1997 of studies showing suicidality in Paxil users. (PL’s Resp. to Def.’s Mot. Summ. J. at 6.) In 1993, the Food and Drug Administration (“FDA”) approved Paxil as safe and effective for use by adults with certain indications, based upon the information that defendants had provided during the FDA’s approval process.

After Paxil’s release, hundreds of cases of suicidality in Paxil users were reported or otherwise published to defendants, including one Paxil user’s murder of his family and subsequent suicide that was the subject of a February 2000 lawsuit (“the Tobin/Sehell litigation”). (PL’s Resp. at 3-4.) Nonetheless, defendants “continued to adhere to the false claim that Paxil suicide risks are not significant enough to warrant action.” (Comply 12.) Of the nine studies that defendants allegedly commissioned on the use of Paxil, it only made public the results of one. (PL’s Resp. at 6.)

In July 2002, Mrs. Hoppe’s doctor prescribed her Paxil to treat her situational depression. She was not suicidal at this time. On September 27, 2002, Mrs. Hoppe committed suicide by hanging.

In April 2004, at the order of the FDA, defendants revised Paxil’s label to add warnings about the risk of suicidality. (PL’s Resp. at 7.) In May 2004, defendants sent a “Dear Doctor” letter to healthcare providers to notify them of the labeling change. (Id.)

On December 2, 2005, before any discovery had been taken, defendants filed their motion for summary judgment.

II. Legal Standard

Federal Rule of Civil Procedure 56(f) provides that where the non-moving party’s affidavits indicate that the non-moving party cannot for the reasons stated present facts essential to justifying its opposition, “the court may refuse the application for judgment or may order a continuance to permit affidavits to be obtained or depositions to be taken or discovery to be had or may make such other order as is just.”

Federal Rule of Civil Procedure 56(c) “mandates the entry of summary judgment, after adequate time for discovery and upon motion, against a party who fails to make a showing sufficient to establish the existence of an element essential to that party’s case, and on which that party will bear the burden of proof at trial.” Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). A factual dispute is “genuine” if the evidence would permit a reasonable jury to find for the non-moving party. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). The court must draw all reasonable inferences from *335 the facts in the light most favorable to the non-moving party. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574, 587, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986); Kornegay v. Cottingham, 120 F.3d 392, 395 (3d Cir.1997).

III. Discussion

Defendants seek summary judgment on all counts. Defendants argue that plaintiffs wrongful death and tort actions (Counts I-IV) are time-barred, and that the remaining counts fail as a matter of law. I find that summary judgment as to Counts I to IV is inappropriate at this stage, but that summary judgment is warranted as to Counts V to VII.

A. Timeliness of wrongful death and tort actions (Counts I-IV)

Under Pennsylvania law, plaintiff had two years after Mrs. Hoppe’s death to timely file this action, or until September 27, 2004. 42 Pa. Cons.Stat. Ann. § 5524. As this action was not commenced until September 26, 2005, it will be time-barred unless the limitations period is tolled for one year. I find that at this stage, summary judgment as to the issue of tolling is premature and the case will proceed to discovery.

1. Which statute of limitations applies

As a threshold matter, Pennsylvania’s statute of limitations for wrongful death and personal injury actions applies to this action. A federal court sitting in diversity must apply the forum state’s choice-of-law rules regarding statutes of limitations. See Guaranty Trust Co. v. York, 326 U.S. 99, 65 S.Ct. 1464, 89 L.Ed. 2079 (1945); Van Buskirk v. Carey Canadian Mines, Ltd., 760 F.2d 481, 487 (3d Cir.1985). Pursuant to Pennsylvania’s so-called “borrowing statute,” Pennsylvania applies its own statute of limitations to causes of action that accrued in a foreign jurisdiction, unless the foreign jurisdiction’s statute of limitations is shorter. 42 Pa. Cons.Stat. Ann. § 5521(b). Here, Pennsylvania’s limitations period for personal injury and wrongful death actions is shorter than Wisconsin’s. Compare 42 Pa. Cons.Stat. Ann. § 5524(2),(7) (two years) loith Wis. Stat. Ann.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gerald v. R.J. Reynolds Tobacco Co.
67 V.I. 441 (Superior Court of The Virgin Islands, 2017)
Arndt v. Johnson & Johnson
67 F. Supp. 3d 673 (E.D. Pennsylvania, 2014)
State Farm Mutual Automobile Insurance v. Cordua
834 F. Supp. 2d 301 (E.D. Pennsylvania, 2011)
Astech International, LLC v. Husick
676 F. Supp. 2d 389 (E.D. Pennsylvania, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
437 F. Supp. 2d 331, 2006 U.S. Dist. LEXIS 46746, 2006 WL 1805968, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hoppe-v-smithkline-beecham-corp-paed-2006.